Federated Hermes Inc. Boosts Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Federated Hermes Inc. increased its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 4.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 807,012 shares of the biotechnology company’s stock after acquiring an additional 33,767 shares during the quarter. Federated Hermes Inc. owned about 0.36% of ADMA Biologics worth $3,648,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GSA Capital Partners LLP boosted its position in shares of ADMA Biologics by 87.7% in the third quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company’s stock worth $867,000 after purchasing an additional 113,184 shares during the period. Qube Research & Technologies Ltd raised its position in shares of ADMA Biologics by 22.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company’s stock valued at $4,313,000 after purchasing an additional 224,696 shares during the period. American Century Companies Inc. lifted its stake in shares of ADMA Biologics by 20.8% during the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after buying an additional 840,761 shares in the last quarter. Aigen Investment Management LP bought a new position in ADMA Biologics in the 3rd quarter worth $140,000. Finally, SG Americas Securities LLC increased its stake in ADMA Biologics by 417.3% in the 4th quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company’s stock worth $421,000 after buying an additional 75,213 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $6.55 on Friday. The business’s 50-day moving average is $6.07 and its 200 day moving average is $4.87. ADMA Biologics, Inc. has a 12 month low of $3.06 and a 12 month high of $6.76. The company has a market capitalization of $1.49 billion, a P/E ratio of -50.38 and a beta of 0.46. The company has a current ratio of 5.16, a quick ratio of 1.69 and a debt-to-equity ratio of 1.04.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The business had revenue of $73.90 million for the quarter, compared to analysts’ expectations of $73.50 million. On average, equities research analysts forecast that ADMA Biologics, Inc. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ADMA. Cantor Fitzgerald boosted their price objective on ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. HC Wainwright restated a “buy” rating and issued a $7.50 price target (up from $6.00) on shares of ADMA Biologics in a research note on Tuesday, March 26th. Finally, Mizuho lifted their price objective on shares of ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, March 1st. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ADMA Biologics has an average rating of “Buy” and a consensus target price of $7.88.

Insider Transactions at ADMA Biologics

In related news, Director Steve Elms sold 49,887 shares of ADMA Biologics stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $6.01, for a total value of $299,820.87. Following the completion of the transaction, the director now owns 2,527,500 shares in the company, valued at $15,190,275. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 639,895 shares of company stock worth $3,927,169 in the last three months. Insiders own 6.00% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.